Evidence map›Paper›PMID 18768388›Full record

ArticleMolecular pharmacology2008

Multiple pharmacophores for the selective activation of nicotinic alpha7-type acetylcholine receptors.

Nicole A Horenstein, Fedra M Leonik, Roger L Papke

Open access · greenAbstract read
In one paragraph

Article in Molecular pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Sulfonium Ligands of the α7 nAChR.Molecules (Basel, Switzerland) · 2021
    Article
  5. Therapeutic Targeting ofPharmacological reviews · 2021
    Review
  6. Review
  7. Article
  8. Cracking the Betel Nut: Cholinergic Activity of Areca Alkaloids and Related Compounds.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2019
    Article
  9. Article
  10. Macroscopic and Microscopic Activation ofMolecular pharmacology · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Nicole A HorensteinDepartment of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida 32610-0267, USA.
Fedra M Leonik
Roger L Papke
University of Florida · US

Funding

Targeting of Alpha7 nAChR for therapeutic effectsR01GM057481 · NIGMS · UNIVERSITY OF FLORIDA · PI PAPKE, ROGER L · 2000 to 2023
$7.6M
NIGMS NIH HHS GM57481NIGMS NIH HHS R01 GM057481
6 · The paper itself

Abstract

The activation of heteromeric and homomeric nicotinic acetylcholine receptors was studied in Xenopus laevis oocytes to identify key structures of putative agonist molecules associated with the selective activation of homomeric alpha7 receptors. We observed that selectivity between alpha7 and alpha4beta2 was more readily obtained than selectivity between alpha7 and alpha3beta4. Based on structural comparisons of previously characterized selective and nonselective agonists, we hypothesize at least three chemical motifs exist that, when present in molecules containing an appropriate cationic center, could be associated with the selective activation of alpha7 receptors. We identify the three distinct structural motifs based on prototypical drugs as the choline motif, the tropane motif, and the benzylidene motif. The choline motif involves the location of an oxygen-containing polar group such as a hydroxyl or carbonyl separated by two carbons from the charged nitrogen. The tropane motif provides alpha7-selectivity based on the addition of multiple small hydrophobic groups positioned away from the cationic center in specific orientations. We show that this motif can convert the nonselective agonists quinuclidine and ethyltrimethyl-ammonium to the alpha7-selective analogs methyl-quinuclidine and diethyldimethyl-ammonium, respectively. We have shown previously that the benzylidene group of 3-2,4, dimethoxy-benzylidene anabaseine (GTS-21) converts anabaseine into an alpha7-selective agonist. The benzylidene motif was also applied to quinuclidine to generate another distinct family of alpha7-selective agonists. Our results provide insight for the further development of nicotinic therapeutics and will be useful to direct future experiments with protein structure-based modeling and site-directed mutagenesis.

Indexed as

Acetylcholinealpha7 Nicotinic Acetylcholine ReceptorAnimalsFemaleHumansModels, MolecularNicotinic AgonistsOocytesProtein SubunitsQuaternary Ammonium CompoundsQuinuclidinesReceptors, NicotinicStereoisomerismStructure-Activity RelationshipXenopus laevisAcetylcholinealpha7 Nicotinic Acetylcholine ReceptorChrna7 protein, humanNicotinic Agonistsnicotinic receptor alpha3beta4nicotinic receptor alpha4beta2Protein SubunitsQuaternary Ammonium CompoundsQuinuclidinesReceptors, Nicotinictetramethylammonium

Identifiers

PMID18768388
PMCPMC2999882
OpenAlexW2058134418

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.